SCHEMBL17010343

SCHEMBL17010343

CC(=O)Oc1ccc(N=C=O)cc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 2/20 0.59
KDM4E B2RXH2 6/20 0.50
HSD17B10 Q99714 4/20 0.50
ALDH1A1 P00352 4/20 0.50
TDP1 Q9NUW8 4/20 0.50
TSHR P16473 3/20 0.50
HPGD P15428 3/20 0.50
PTGS1 P23219 2/20 0.50
PTGS2 P35354 2/20 0.50
BLM P54132 2/20 0.50
ESR1 P03372 1/20 0.50
ITGB3 P05106 1/20 0.50
ITGA2B P08514 1/20 0.50
HMGB1 P09429 1/20 0.50
GGT1 P19440 1/20 0.50
NAPRT Q6XQN6 1/20 0.50
LMNA P02545 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9491045 0.84 TSHR (0.50) CFDKDM4EALDH1A1TDP1TSHR
SCHEMBL24074136 0.83 CFD (0.65) CFDKDM4EHSD17B10ALDH1A1TDP1
SCHEMBL4163589 0.81 TRPA1 (0.49) CFDKDM4EHSD17B10ALDH1A1TDP1
SCHEMBL11184869 0.80 TSHR (0.54) KDM4EALDH1A1TDP1TSHRHPGD
SCHEMBL16715329 0.75 CFD (1.00) CFDKDM4EHSD17B10ALDH1A1TDP1
SCHEMBL25027 0.75 CFD (0.73) CFDKDM4EHSD17B10ALDH1A1TDP1
SCHEMBL1099682 0.75 ALDH1A1 (0.54) KDM4EHSD17B10ALDH1A1TDP1HPGD
SCHEMBL344505 0.74 KDM4E (0.74) CFDKDM4EHSD17B10ALDH1A1TDP1
SCHEMBL344489 0.74 CFD (0.71) CFDKDM4EHSD17B10ALDH1A1TDP1
SCHEMBL1317371 0.74 CFD (0.71) CFDKDM4EHSD17B10ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10093631-B2 Bifunctional compounds and use for reducing uric acid levels ACQUIST LLC (US) 2018-10-09 US disclosed
US-20170197923-A1 Bifunctional Compounds and Use for Reducing Uric Acid Levels ACQUIST LLC 2017-07-13 US disclosed
EP-3104861-A1 BIFUNCTIONAL COMPOUNDS AND USE FOR REDUCING URIC ACID LEVELS Warrell, Raymond P., Jr. (US) 2016-12-21 EP disclosed
WO-2015123003-A1 BIFUNCTIONAL COMPOUNDS AND USE FOR REDUCING URIC ACID LEVELS WARRELL RAYMOND P (US) 2015-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197923-A1 Bifunctional Compounds and Use for Reducing Uric Acid Levels XDH, OAT, ATIC CFD 1897/4885KDM4E 4691/4885HSD17B10 967/4885
US-10093631-B2 Bifunctional compounds and use for reducing uric acid levels XDH, OAT, ATIC CFD 1897/4885KDM4E 4691/4885HSD17B10 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.